Market Closed -
Nasdaq
16:00:00 2024-07-17 EDT
5-day change
1st Jan Change
0.943
USD
-0.47%
+12.45%
-2.03%
Presenter SpeechJessica Fye (Analysts)Good morning, everyone. Thanks for joining us. My name i...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transcript : Chimerix, Inc., Q1 2024 Earnings Call, May 01, 2024
05-01
Chimerix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-01
CI
Chimerix Appoints Marc D. Kozin to Board of Directors
03-21
CI
Transcript : Chimerix, Inc., Q4 2023 Earnings Call, Feb 29, 2024
02-29
Chimerix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
02-29
CI
Chimerix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
02-29
CI
Earnings Flash (CMRX) CHIMERIX Reports Q4 Revenue $4,000, vs. Street Est of $70,000
02-29
MT
Chimerix Announces Board Changes
12-29
CI
Chimerix Names Michelle LaSpaluto Finance Chief
12-04
MT
Chimerix, Inc. Promotes Michelle Laspaluto to the Position of Chief Financial Officer
12-04
CI
Chimerix, Inc. Appoints Thomas Riga as Chief Operating and Commercial Officer
11-16
CI
Transcript : Chimerix, Inc., Q3 2023 Earnings Call, Nov 02, 2023
11-02
Earnings Flash (CMRX) CHIMERIX Posts Q3 Revenue $11,000, vs. Street Est of $90,000
11-02
MT
Chimerix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-02
CI
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery
23-08-16
CI
Transcript : Chimerix, Inc., Q2 2023 Earnings Call, Aug 03, 2023
23-08-03
Earnings Flash (CMRX) CHIMERIX Posts Q2 Revenue $26,000, vs. Street Est of $270,000
23-08-03
MT
Chimerix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-03
CI
Chimerix Names Michael Andriole as Chief Executive Officer
23-06-27
MT
Chimerix, Inc. Announces CEO Changes, Effective on August 1, 2023
23-06-27
CI
Chimerix, Inc. Announces Executive Changes, Effective on August 1, 2023
23-06-27
CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell Small Cap Comp Value Index
23-06-23
CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 3000 Index
23-06-23
CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell Small Cap Completeness Index
23-06-23
CI
Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2500 Value Index
23-06-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with differential specificity and function. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. The Chimerix Chemical Library contains over 10,000 heterocyclic ring systems and nucleosides, also includes approximately 3,500 nucleosides.
More about the company
Last Close Price
0.943
USD
Average target price
7
USD
Spread / Average Target
+642.31%
Consensus
1st Jan change
Capi.
-2.03% 84.52M +20.03% 126B +23.61% 117B +22.91% 27.52B -18.07% 20.87B -14.29% 17.01B -14.81% 16.26B +9.78% 14.56B -46.10% 15.09B +52.34% 13.89B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1